Skip to main content
×
×
Home

Emergence and Control of Fluoroquinolone-Resistant, Toxin A–Negative, Toxin B–Positive Clostridium difficile

  • Denise Drudy (a1), Norma Harnedy (a2), Séamus Fanning (a1), Margaret Hannan (a3) and Lorraine Kyne (a2)...
Abstract
Background.

Clostridium difficile is a major cause of infectious diarrhea in hospitalized patients. Between August 2003 and January 2004, we experienced an increase in the incidence of C. difficile–associated disease. We describe the investigation into and management of the outbreak in this article.

Methods.

A total of 73 consecutive patients with nosocomial C. difficile–associated diarrhea were identified. C. difficile isolates were characterized using toxin-specific enzyme immunoassays, a tissue-culture fibroblast cytotoxicity assay, polymerase chain reaction (PCR), and antimicrobial susceptibility tests. Rates of recurrence and of C. difficile colitis were recorded. Changes in antibiotic use and infection control policies were documented.

Results.

The incidence of C. difficile–associated diarrhea peaked at 21 cases per 1,000 patient admissions. Of the C. difficile isolates recovered, 85 (95%) were identical toxin A–negative and toxin B-positive strains, corresponding to toxinotype VIII and PCR ribotype 017. All clonal isolates were resistant to multiple antibiotics, including ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin, and gatifloxacin (minimum inhibitory concentrations [MICs] of greater than 32 μg/mL) and erythromycin, clarithromycin, and clindamycin (MICs of greater than 256 μg/mL). Recurrent C. difficile–associated disease occurred in 26 (36%) of the patients. At least 10 (14%) of the patients developed C. difficile colitis. Additional infection control measures introduced included the use of ward memos, a hand-hygiene awareness campaign, increased environmental cleaning, attention to prescribing practices for antibiotics, increased awareness of diarrheal illness, and early isolation of affected patients. Total use of fluoroquinolones did not change throughout the study period. Despite persistence of this toxin-variant strain, the incidence of C. difficile–associated disease in our institution decreased to fewer than 5 cases per 1,000 admissions.

Conclusions.

We report on the emergence of a fluoroquinolone- and clindamycin-resistant, toxin A–negative, and toxin B–positive strain of C. difficile associated with an outbreak of C. difficile–associated disease in our institution during a 6-month period. We found that careful attention to improvement of infection control interventions was the most important means of controlling this nosocomial pathogen.

Copyright
Corresponding author
Consultant Physician in Medicine for the Older Person, Mater Misericordiae University Hospital, 44 Eccles St., Dublin 7, Ireland (lkyne@mater.ie)
References
Hide All
1. Kelly, CP, LaMont, JT. Clostridium difficile infection. Ann Rev Med 1998;49:375390.
2. Kyne, L, Warny, M, Qamar, A, Kelly, CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390397.
3. Warny, M, Pepin, J, Fang, A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:10791084.
4. Noren, T. Outbreak from a high-toxin intruder: Clostridium difficile . Lancet 2005;366:10531054.
5. Pepin, J, Saheb, N, Coulombe, MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile–associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:12541260.
6. Johnson, S, Samore, MH, Farrow, KA, et al. Epidemics of diarrhea caused by a ciindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999;341:16451651.
7. Wilcox, MH, Fawley, W, Freeman, J, et al. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2000;46:551556.
8. Gaynes, R, Rimland, D, Killum, E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640645.
9. Muto, CA, Pokrywka, M, Shutt, K, et al. A large outbreak of Clostridium difficile–associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273280.
10. Pepin, J, Valiquette, L, Alary, ME, et al. Clostridium difficile–associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466472.
11. McEllistrem, MC, Carman, RJ, Gerding, DN, Genheimer, CW, Zheng, L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005;40:265272.
12. Kyne, L, Sougioultzis, S, McFarland, LV, Kelly, CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002;23:653659.
13. Rupnik, M, Braun, V, Soehn, F, et al. Characterization of polymorphisms in the toxin A and B genes of Clostridium difficile . FEMS Microbiol Lett 1997;148:197202.
14. Rupnik, M. How to detect Clostridium difficile variant strains in a routine laboratory. Clin Microbiol Infect 2001;7:417420.
15. Stubbs, SL, Brazier, JS, O'Neill, GL, Duerden, BI. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999;37:461463.
16. Chaves-Olarte, E, Low, P, Freer, E, et al. A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins. J Biol Chem 1999;274:1104611052.
17. Boyce, JM, Ligi, C, Kohan, C, Dumigan, D, Havill, NL. Lack of association between the increased incidence of Clostridium difficile–associated disease and the increasing use of alcohol-based hand rubs. Infect Control Hosp Epidemiol 2006;27:479483.
18. Gordin, F, Gordin, FM, Schultz, ME, Huber, RA, Gill, JA. Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. Infect Control Hosp Epidemiol 2005;26:650653.
19. Johnson, S, Sambol, SP, Brazier, JS, et al. International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants. J Clin Microbiol 2003;41:15431547.
20. Brazier, JS, Mulligan, ME, Delmee, M, Tabaqchali, S. Preliminary findings of the international typing study on Clostridium difficile. International Clostridium difficile Study Group. Clin Infect Dis 1997;25(suppl 2): S199S201.
21. Brazier, JS, Stubbs, SL, Duerden, BI. Prevalence of toxin A negative/B positive Clostridium difficile strains. J Hosp Infect 1999;42:248249.
22. Barbut, F, Lalande, V, Burghoffer, B, Thien, HV, Grimprel, E, Petit, JC. Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. J Clin Microbiol 2002;40:20792083.
23. Al-Barrak, A, Embil, J, Dyck, B, et al. An outbreak of toxin A negative, toxin B positive Clostridium difficile–associated diarrhea in a Canadian tertiary-care hospital. Can Commun Dis Rep 1999;25:6569.
24. Kuijper, EJ, de Weerdt, J, Kato, H, et al. Nosocomial outbreak of Clostridium difficile–associated diarrhoea due to a clindamycin-resistant enterotoxin Anegative strain. Eur J Clin Microbiol Infect Dis 2001;20:528534.
25. Drudy, D, Quinn, T, O'Mahony, R, Kyne, L, O'Gaora, P, Fanning, S. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile . J Antimicrob Chemother 2006;58:12641267.
26. Drudy, D, Harnedy, N, Fanning, S, O'Mahony, R, Kyne, L. Isolation and characterization of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland. Clin Microbiol Infect 2007;13:298304.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Infection Control & Hospital Epidemiology
  • ISSN: 0899-823X
  • EISSN: 1559-6834
  • URL: /core/journals/infection-control-and-hospital-epidemiology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 3 *
Loading metrics...

Abstract views

Total abstract views: 203 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 19th September 2018. This data will be updated every 24 hours.